Company: Pfizer Inc.
Ticker: PFE
Form: 10-K
Filed: 2026-02-26
Fiscal Period: {"fp": "FY", "fy": 2025}

Question: What was Pfizer Inc.'s net income in fiscal year 2025?
Question Type: value_lookup

Concept: NetIncomeLoss
Answer (Numeric): 7771.0
Answer (Display): $7,771 million
Unit: USD millions

Evidence:
[{"chunk_id": "210", "equivalent_chunk_ids": ["210"], "section": "Consolidated Statements of Operations", "supports": ["main"], "text": "Pfizer Inc. and Subsidiary Companies\nYear Ended December 31,\n(MILLIONS, EXCEPT PER SHARE DATA)\nRevenues:\nProduct revenues\n51,663\n53,816\n50,914\nAlliance revenues\n9,266\n8,388\n7,582\nRoyalty revenues\n1,650\n1,423\n1,058\nTotal revenues\n62,579\n63,627\n59,553\nCosts and expenses:\nCost of sales\n(a), (b)\n16,067\n17,851\n24,954\nSelling, informational and administrative expenses\n(a)\n13,794\n14,730\n14,771\nResearch and development expenses\n(a)\n10,437\n10,822\n10,679\nAcquired in-process research and development expenses\n1,613\nAmortization of intangible assets\n4,874\n5,286\n4,733\nRestructuring charges and certain acquisition-related costs\n1,550\n2,419\n2,943\nOther (income)/deductions––net\n6,724\n4,388\nIncome from continuing operations before provision/(benefit) for taxes on income\n7,520\n8,023\n1,058\nProvision/(benefit) for taxes on income\n1,115\nIncome from continuing operations\n7,787\n8,051\n2,172\nDiscontinued operations––net of tax\nNet income before allocation to noncontrolling interests\n7,812\n8,062\n2,158\nLess: Net income attributable to noncontrolling interests\nNet income attributable to Pfizer Inc. common shareholders\n7,771\n8,031\n2,119\nEarnings per common share––basic\nIncome from continuing operations attributable to Pfizer Inc. common shareholders\n1.37\n1.42\n0.38\nDiscontinued operations––net of tax\nNet income attributable to Pfizer Inc. common shareholders\n1.37\n1.42\n0.38\nEarnings per common share––diluted\nIncome from continuing operations attributable to Pfizer Inc. common shareholders\n1.36\n1.41\n0.37\nDiscontinued operations––net of tax\nNet income attributable to Pfizer Inc. common shareholders\n1.36\n1.41\n0.37\nWeighted-average shares––basic\n5,683\n5,664\n5,643\nWeighted-average shares––diluted\n5,713\n5,700\n5,709\n(a)\nExclusive of amortization of intangible assets.\n(b)\nSee\nNote\n17A\nSee Accompanying Notes.\nPfizer Inc.\n2025 Form 10-K"}]

Derivation: